The pharmacologic management of premenstrual dysphoric disorder (Q56341305)

Expert Opinion on Pharmacotherapy

Europe PubMed Central

title

The pharmacologic management of premenstrual dysphoric disorder (English)

0 references

1 reference

Andrea J Rapkin

1

0 references

Sharon A Winer

series ordinal

2

0 references

language of work or name

English

0 references

publication date

28 January 2008

0 references

published in

0 references

volume

9

0 references

issue

3

0 references

page(s)

429-445

0 references

cites work

Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Prevalence, incidence and stability of premenstrual dysphoric disorder in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

The menstrual cycle and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

The etiology, biology, and evolving pathology of premenstrual syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Impact of oral contraceptive pill use on premenstrual mood: predictors of improvement and deterioration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Pathogenesis in menstrual cycle-linked CNS disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Regulation of progestin receptors in raphe neurons of steroid-treated monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Role of 5-HT in stress, anxiety, and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Exploratory study of premenstrual symptoms and serotonin variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Neuroendocrine response to an intravenous L-tryptophan challenge in women with premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Mood changes correlate to changes in brain serotonin precursor trapping in women with premenstrual dysphoria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Acute tryptophan depletion aggravates premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Effects of metergoline on symptoms in women with premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

From ion currents to genomic analysis: recent advances in GABAA receptor research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Progesterone metabolite allopregnanolone in women with premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

GABA receptors, progesterone and premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Withdrawal properties of a neuroactive steroid: implications for GABA(A) receptor gene regulation in the brain and anxiety behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Neurosteroids in depression: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Fluoxetine in the treatment of premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

The premenstrual symptoms screening tool (PSST) for clinicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Venlafaxine in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Premenstrual daily fluoxetine for premenstrual dysphoric disorder: a placebo-controlled, clinical trial using computerized diaries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Fluvoxamine in the treatment of menstrually related mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Oral contraceptives and neuroactive steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacological characterization in animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Use of leuprolide acetate plus tibolone in the treatment of severe premenstrual syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

The effectiveness of GnRHa with and without 'add-back' therapy in treating premenstrual syndrome: a meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Prevention of bone loss and hypoestrogenic symptoms by estrogen and interrupted progestogen add-back in long-term GnRH-agonist down-regulated patients with endometriosis and premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Range of published estimates of venous thromboembolism incidence in young women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

European active surveillance study of women taking HRT (EURAS-HRT): study protocol [NCT00214903].

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Compliance to antidepressant drug therapy for treatment of premenstrual syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Oral contraceptive discontinuation: do side effects matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429

Prevalence of premenstrual dysphoric disorder in female patients with seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.9.3.429